logo
Intracranial small lymphocytic lymphoma
Dyskeratosis congenita
The evolving use of serum free light chain assays in haematology
Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma
Eight-year median survival in multiple myeloma after total therapy 2
Mutated and non-mutated TP53 as targets in the treatment of leukaemia
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication
Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells
Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib
Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma
β-Dystroglycan modulates the interplay between actin and microtubules in human-adhered platelets
Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population – results from the HUNT 2 study
The VWF/ADAMTS13 axis in the antiphospholipid syndrome
The effect of anti-CD40 ligand in immune thrombocytopenic purpura
Erythrocyte vesiculation
The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms
Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma
t(14;19)(q32;q13) incidence and significance in B-cell lymphoproliferative disorders
British Blood Transfusion Society 26th Annual Scientific Meeting